再生リスト 最初から再生 R&D Day Forward-Looking Statements Participants 1. Opening 5-Year Business Plan (FY2021-FY2025) for Sustainable Growth Strategic Pillars for the 5-Year Business Plan (FY2021-FY2025) Progress since R&D Day 2021 Progress since R&D Day 2021 Dato-DXd, HER3-DXd and Alpha DS Strategy to Enrich Delivery to Patients 2. Clinical Progress Progress in Breast Cancer Practice-changing achievement in HER2 low BC Pioneer HER2 low BC as a new clinically meaningful patient segment SABCS 2022 Highlights Data further supports the 2L SOC in HER2+ BC Data further supports the 2L SOC in HER2+ BC Phase 3 results confirm the favorable profile ENHERTU Breast Cancer Summary Reported the first data in HR+/HER2- BC Continues to demonstrate encouraging data in TNBC Dato-DXd+durvalumab shows a high ORR in TNBC New clinical study: TROPION-Breast03 Dato-DXd Breast Cancer Summary Progress in Lung Cancer Clinically meaningful responses in HER2 mut NSCLC ENHERTU for HER2 mutant NSCLC Data supports further development in 1L NSCLC Two Ph3 studies addressing 1L NSCLC without AGA Lung Cancer Summary Rising Stars and Hematology Rising Stars follow 3ADCs as potential new growth drivers Promising efficacy in multiple cancer types Promising efficacy in multiple cancer types Encouraging data supports further development Changing SOC for newly-diagnosed FLT3-ITD AML World first EZH1/EZH2 dual inhibitor approved for adult T-cell leukemia-lymphoma Next steps of Rising Stars and Hematology 3. R&D Strategy Expand & Extend to deliver our technology to more patients Our Breast Cancer Strategy Establish and expand DXd-ADCs to address the broader spectrum of Breast Cancer Our Lung Cancer Strategy Establish and expand DXd-ADCs as new treatment options in Lung Cancer Combinations to expand DXd-ADC’s opportunity Translational Science supports our combo/sequencing strategy 4. Closing Creating “One Global R&D” to deliver our strong pipeline Plan to enhance Research to Development capability Daiichi Sankyo R&D toward 2025 and beyond Daiichi Sankyo’s Purpose and R&D Vision 5. Q&A Q&A1 Q&A2 Q&A3 Q&A4 Q&A5 Sunao Manabe President and CEO Wataru Takasaki Executive Officer, Head of R&D Division & Vice President of Precision Medicine Function Ken Takeshita Head of Global R&D Mark Rutstein Head of Global Oncology Development
